Security Snapshot

TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) Institutional Ownership

CUSIP: 88338N206

13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

41

Shares (Excl. Options)

3,384,889

Price

$1.63

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
TXMD on Nasdaq
Shares outstanding
11,676,558
Price per share
$2.00
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
3,384,889
Total reported value
$5,517,397
% of total 13F portfolios
0%
Share change
+81,101
Value change
+$146,413
Number of holders
41
Price from insider filings
$2.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 88338N206.
  • 41 institutions reported positions in Q4 2025.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 41 to 3 between Q4 2025 and Q1 2026.
  • Reported value moved from $5,517,397 to $185.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 41 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 88338N206?
CUSIP 88338N206 identifies TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Clearline Capital LP 5.5% $705,096 635,222 Clearline Capital LP 31 Dec 2024
Baselake Partners, LP 5.2% $1,384,373 607,181 Baselake Partners, LP 30 Mar 2026

As of 31 Dec 2025, 41 institutional investors reported holding 3,384,889 shares of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD). This represents 29% of the company’s total 11,676,558 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) together control 29% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 10% 1,192,191 0% 0.02% $1,943,271
Clearline Capital LP 5.4% 635,222 0% 0.08% $1,035,412
VANGUARD GROUP INC 3.4% 397,056 +5.4% 0% $647,201
Tejara Capital Ltd 3% 350,852 +1.9% 0.24% $571,889
ADAR1 Capital Management, LLC 1.8% 209,210 0% 0.03% $341,012
MORGAN STANLEY 1.1% 129,217 -1% 0% $210,624
BlackRock, Inc. 0.99% 116,132 0% 0% $189,295
GEODE CAPITAL MANAGEMENT, LLC 0.91% 106,100 -2.7% 0% $172,984
RENAISSANCE TECHNOLOGIES LLC 0.83% 96,500 +172% 0% $157,295
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.3% 35,164 0% $57,317
STATE STREET CORP 0.26% 30,100 0% 0% $49,063
CITADEL ADVISORS LLC 0.24% 28,240 -18% 0% $46,031
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.15% 17,000 -50% 0% $27,710
NORTHERN TRUST CORP 0.14% 16,448 -0.05% 0% $26,811
OSAIC HOLDINGS, INC. 0.08% 9,297 +936% 0% $15,153
FMR LLC 0.07% 8,290 +0.01% 0% $13,513
Tower Research Capital LLC (TRC) 0.02% 2,471 -9.6% 0% $4,028
GROUP ONE TRADING LLC 0.01% 1,596 0% $2,601
UBS Group AG 0.01% 1,114 +208% 0% $1,815
NATIONAL BANK OF CANADA /FI/ 0.01% 610 -9% 0% $976
Smartleaf Asset Management LLC 0.01% 601 0% $986
JPMORGAN CHASE & CO 0% 293 0% 0% $477
SBI Securities Co., Ltd. 0% 255 0% 0% $416
US BANCORP \DE\ 0% 246 0% 0% $401
BNP PARIBAS FINANCIAL MARKETS 0% 226 0% 0% $368

Institutional Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 92 $185 +$2 $2.00 3
2025 Q4 3,384,889 $5,517,397 +$146,413 $1.63 41
2025 Q3 3,303,788 $3,542,705 +$51,253 $1.08 43
2025 Q2 3,255,627 $3,776,528 -$96,760 $1.16 39
2025 Q1 3,343,589 $3,092,849 -$161,728 $0.92 39
2024 Q4 3,528,745 $3,034,778 +$127,744 $0.86 38
2024 Q3 3,379,026 $5,609,223 -$32,659 $1.66 34
2024 Q2 3,408,566 $5,487,879 -$167 $1.61 34
2024 Q1 3,377,053 $7,732,812 +$286,534 $2.29 43
2023 Q4 3,251,877 $7,316,577 -$358,133 $2.25 36
2023 Q3 2,987,555 $9,324,433 +$112,168 $3.02 36
2023 Q2 3,031,054 $12,488,021 -$296,992 $4.12 40
2023 Q1 3,115,140 $11,682,289 -$1,635,363 $3.75 38
2022 Q4 3,475,915 $19,431,091 +$6,039,029 $5.59 43
2022 Q3 2,070,807 $13,750,198 -$489,469 $6.64 29
2022 Q2 1,993,507 $19,835,726 +$19,831,622 $9.95 36
2022 Q1 10,800 $4,104 +$304 $0.38 2
2021 Q4 10,000 $3,555 $0.36 1